Reuters quotes “sources with knowledge of the matter” as having said that the sales are part of a wider retreat from “sub-scale Asian markets” and could fetch around $150m.
Aviva declined to comment on the rumour, with a spokesperson informing International Adviser that Aviva “does not comment on this type of market speculation”.
In its Q1 interim management statement last week, the UK’s second largest insurer announced a strategic review of its business which will see it exit some markets.
Within the statement Aviva’s executive deputy chairman John McFarlane said: “[Aviva would conduct] a strategic review of all our businesses to ensure we are focused on the right segments; that we put in place plans to advance the performance and position of our businesses strategically, and exit sensibly those that are not part of our future.
“These will be reviewed by me and subsequently the Board in June, and we will provide an update to you in July.”
